Therapeutic expansion of protective effector and memory T-cell responses against SARS-CoV-2

  • Funded by Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
  • Total publications:0 publications

Grant number: 01KI2072A

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $299,548.81
  • Funder

    Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
  • Principle Investigator

    Pending
  • Research Location

    Germany, Europe
  • Lead Research Institution

    Otto-von-Guericke Universität Magdeburg Freie Universität Berlin
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    Gender

  • Study Subject

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Abstract: "T cells destroy virus-infected host cells and regulate the production of virus-neutralizing antibodies to prevent the virus from entering the cell and multiplying. To instruct T cells viral components must be presented by MHC molecules alongside costimulatory molecules on antigen-presenting cells. MHC molecules show a high degree of variation across the population and the distribution of these variants (allotypes) vary significantly between individuals and ethnicities. Thus, T cell responses are significantly tailored by the combination of an MHC allotype and the presented viral peptide. Recombinantly expressed MHC allotypes will be loaded with in silico predicted and verified viral peptides. Using these sets together with newly discovered costimulatory molecules for T cells will enable us to expand and visualize specific T-cell responses of small subpopulations. The novel approach will be used to characterize the T-cell responses of recovered SARS-CoV-2-infected individuals to determine their effector and memory response which mediated protection/cure. Results will be compared to T-cell responses of COVID-19 patients in the first phase of the disease for prediction of disease outcome. In perspective, the novel approach can also be utilized to expand and manipulate SARS-CoV-2-specific T-cell responses as cellular therapy for COVID-19 patients. Our results will provide novel insights into the mechanisms of cellular adaptive immune responses against the still largely unknown SARS-CoV-2 virus, which could form a basis for diagnosis and future therapy of this infection."; Research Type: discovery; Study population: not applicable